Country: United States
Language: English
Source: NLM (National Library of Medicine)
CEFTRIAXONE SODIUM (UNII: 023Z5BR09K) (CEFTRIAXONE - UNII:75J73V1629)
Sandoz GmbH
INTRAVENOUS
PRESCRIPTION DRUG
Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, USP and other antibacterial drugs, ceftriaxone for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone for injection, USP is indicated for the treatment of the following infections when caused by susceptible organisms: Caused by Streptococcus pneumoniae , Staphylococcus aureus, Ha
Ceftriaxone for injection, USP sterile powder is available in Pharmacy Bulk Package bottle containing 10 g equivalent of ceftriaxone. Box of 1 (43858-635-00). Other Size Packages Available: Ceftriaxone for Injection, USP is also supplied as a sterile crystalline powder in glass vials as follows: Vials containing 250 mg equivalent to ceftriaxone. Package of 10 (43858-631-01). Vials containing 500 mg equivalent to ceftriaxone. Package of 10 (43858-632-01). Vials containing 1 g equivalent to ceftriaxone. Package of 10 (43858-633-01). Vials containing 2 g equivalent to ceftriaxone. Package of 10 (43858-634-01). Vials containing 250 mg equivalent to ceftriaxone. Package of 1 (43858-631-00). Vials containing 500 mg equivalent to ceftriaxone. Package of 1 (43858-632-00). Vials containing 1 g equivalent to ceftriaxone. Package of 1 (43858-633-00). Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light.
Abbreviated New Drug Application
CEFTRIAXONE SODIUM- CEFTRIAXONE SODIUM INJECTION, POWDER, FOR SOLUTION SANDOZ GMBH ---------- CEFTRIAXONE FOR INJECTION, USP RX ONLY PHARMACY BULK PACKAGE NOT FOR DIRECT INFUSION To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, and other antibacterial drugs, ceftriaxone for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. DESCRIPTION Ceftriaxone for injection, USP is a sterile, semisynthetic, broad-spectrum cephalosporin antibiotic for intravenous or intramuscular administration. Ceftriaxone sodium is (6_R_, 7_R_)-7-[2-(2-Amino-4-thiazolyl) glyoxylamido]-8-oxo-3-[[(1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-_as_-triazin-3-yl)thio]methyl]-5-thia-1- azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7 -(_Z_)-(_O_-methyloxime), disodium salt, sesquaterhydrate. The chemical formula of ceftriaxone sodium is C H N Na O S •3.5H O. It has a calculated molecular weight of 661.60 and the following structural formula: Ceftriaxone sodium is a white to yellowish crystalline powder which is readily soluble in water, sparingly soluble in methanol and very slightly soluble in ethanol. The pH of a 1% aqueous solution is approximately 6.7. The color of ceftriaxone sodium solutions ranges from light yellow to amber, depending on the length of storage, concentration and diluent used. Each Pharmacy Bulk Package is supplied as a dry powder in Pharmacy Bulk Package bottles containing sterile ceftriaxone sodium, USP equivalent to 10 grams of ceftriaxone and is intended for intravenous infusion only. Ceftriaxone sodium contains approximately 83 mg (3.6 mEq) of sodium per gram of ceftriaxone activity. A Pharmacy Bulk Package is a container of a sterile preparation for parenteral use that contains many single doses. The contents are intended for use in a pharmacy admixture program and are restricted to the preparation of admixtures for intravenous infusion. FURTHER DILUTION IS REQUIRED BEFORE USE. (See DOSAGE Read the complete document